Baseline characteristics of participants included in the study
| Overall (n=1348) | Hand OA status | |||
|---|---|---|---|---|
| No hand OA (n=622) | Radiographic OA (n=540) | Symptomatic OA (n=186) | ||
| Age (years) (mean (SD)) | 62.2 (8.2) | 57.6 (6.4) | 66.1 (7.6) | 66.6 (7.1) |
| Sex (n (%) female) | 725/1348 (53.8) | 303/622 (48.7) | 284/540 (74.2) | 138/186 (74.2) |
| BMI (kg/m2) (mean (SD)) | 27.6 (4.6) (n=1347) | 27.4 (4.5) | 27.8 (4.9) | 28.0 (4.4) |
| No of symptomatic hand OA joints (median (IQR)) (range 0–30) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 2 (1, 4) |
| No of joints with radiographic OA (range 0–30) | 1 (0, 5) | 0 (0, 0) | 4 (2, 7) | 8 (3, 13) |
| No of painful finger joints (range 0–30) | 0 (0, 1) | 0 (0, 0) | 0 (0, 0) | 6 (2, 11) |
| No of painful joints in lower limb (median (IQR)) (range 0–8) | 0 (0, 2) | 0 (0, 2) | 0 (0, 2) | 0 (0, 2) |
| Comorbidities and risk factors | ||||
| Increased blood pressure (n (%)) | 98/1346 (7.3) | 31/622 (5.0) | 48/538 (8.9) | 19/186 (10.2) |
| Total cholesterol:HDL ratio, mean (SD) | 4.6 (1.5) | 4.6 (1.6) | 4.5 (1.4) | 4.5 (1.4) |
| Increased fasting/non-fasting blood glucose (n (%)) | 101/1338 (7.5) | 38/619 (6.1) | 49/536 (9.1) | 14/183 (7.7) |
| Self-reported previous cancer (n (%)) | 282/1342 (21.0) | 114/622 (18.3) | 120/536 (22.4) | 48/184 (26.1) |
| Smoking (current/previous) (n (%)) | 605/1348 (44.9) | 316/622 (50.8) | 219/540 (40.6) | 70/186 (37.6) |
| Alcohol consumption (n (%)) | 887/1347 (65.7) | 425/621 (68.4) | 343/540 (63.5) | 119/186 (64.0) |
| Low physical activity (n (%)) | 414/1252 (33.3) | 177/577 (30.7) | 174/496 (35.1) | 63/171 (36.8) |
| Previous events (before examination cycle 22 in the Original cohort and before examination cycle 5 in the Offspring cohort) | ||||
| Cardiovascular events (n (%)) | 92/1348 (6.8) | 37/622 (5.9) | 40/540 (7.4) | 15/186 (8.1) |
| Coronary heart disease (n (%)) | 75/1348 (5.6) | 31/622 (5.0) | 32/540 (5.9) | 12/186 (6.5) |
| Congestive heart failure (n (%)) | 19/1348 (1.4) | 5/622 (0.8) | 10/540 (1.9) | 4/186 (2.2) |
| Atherothrombotic brain infarction (n (%)) | 13/1348 (1.0) | 6/622 (1.0) | 5/540 (0.9) | 2/186 (1.1) |
| Medication | ||||
| Current antihypertensive treatment (n (%)) | 371/1338 (27.7) | 123/621 (19.8) | 174/534 (33.3) | 70/183 (38.3) |
| Current lipid lowering treatment (n (%)) | 139/1348 (10.3) | 59/622 (9.5) | 53/540 (9.8) | 27/186 (14.5) |
| Current antidiabetic treatment (oral/insulin) (n (%)) | 52/1348 (3.9) | 16/622 (2.6) | 25/540 (4.6) | 11/186 (5.9) |
| Current NSAIDs (n (%)) | 163/1347 (12.1) | 66/621 (10.6) | 62/540 (11.5) | 35/186 (18.8) |
| Daily aspirin (n (%)) | 258/1333 (19.4) | 87/616 (14.1) | 126/533 (23.6) | 45/184 (24.5) |
BMI, body mass index; HDL, high density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis.